Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
Cara Therapeutics (Nasdaq: CARA) will have its CEO, Christopher Posner, present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 9:30 a.m. ET. The presentation will focus on the company's innovative treatment for pruritus, notably its FDA-approved KORSUVA™ injection for kidney disease patients. An archived recording will soon be available on the company’s website for 30 days. Cara is also developing an oral difelikefalin formulation and conducting clinical trials for various pruritus-related conditions.
- None.
- None.
STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET.
A webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
FAQ
When is Cara Therapeutics presenting at the Canaccord Genuity 42nd Annual Growth Conference?
Who is presenting for Cara Therapeutics at the conference?
What product is Cara Therapeutics known for?
Where can I watch the Cara Therapeutics presentation?
What is the ticker symbol for Cara Therapeutics?
